Laroscorbine

Ascorbic Acid, the active ingredient in Laroscorbine, is a vitamin presented as an aqueous solution for intravenous use. It is employed to correct vitamin C deficiency and to support immune function in patients requiring parenteral nutrition or at risk of scurvy.

GNH USA supplies Laroscorbine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology units worldwide, adhering to EU GMP standards and providing batch‑tested product for global distribution.

Laroscorbine is used in the management of conditions related to vitamin C deficiency and immune support.

- Vitamin C deficiency (scurvy): restores normal plasma ascorbate levels and resolves classic scurvy symptoms. - Immune support: provides adjunctive antioxidant support to enhance immune cell function during acute illness. - Parenteral nutrition: supplies essential vitamin C to patients unable to receive oral nutrition, ensuring adequate micronutrient intake.

Adverse reactions to intravenous ascorbic acid are generally infrequent but may occur.

Common Side Effects: - Infusion site irritation or pain. - Mild nausea or vomiting. - Transient headache or flushing. - Temporary hypotension during infusion.

Serious or Rare Side Effects: - Oxalate nephropathy leading to renal impairment. - Hemolysis in patients with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency. - Anaphylactic or severe allergic reactions. - Severe hypotension requiring medical intervention. - Acute renal failure in susceptible individuals.

When using Laroscorbine, consider the following safety measures. - Assess renal function: monitor serum creatinine before and during therapy. - Screen for G6PD deficiency: avoid use in deficient patients. - Avoid concurrent high‑dose calcium: may increase risk of precipitation. - Monitor blood pressure: watch for hypotension during infusion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Laroscorbine may interact with other medicines; awareness of potential interactions is important.

Major Interactions (Avoid): - Concurrent oxalate‑producing agents (e.g., ethylene glycol): increase risk of renal oxalate deposition. - High‑dose chemotherapy agents that generate free radicals: possible antagonistic effect. - Certain point‑of‑care glucose meters: high vitamin C can cause falsely low glucose readings.

Moderate Interactions (Monitor Closely): - Loop diuretics: may increase urinary excretion of vitamin C, altering plasma levels. - Iron supplements: enhanced iron absorption may lead to overload in susceptible patients. - Anticoagulants (e.g., warfarin): high vitamin C intake may potentiate anticoagulant effect.